Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma


  • Hadi Atabati Leishmaniasis Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
  • Amir Raoofi Student Research Committee, Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Abdollah Amini Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Reza Masteri Farahani Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran




Invasive Breast Cancer, Her2, IHC, CISH


BACKGROUND: In patients with breast cancer, HER2 gene expression is of a great importance in reacting to Herceptin treatment. To evaluate this event, immunohistochemistry (IHC) has been done routinely on the basis of scoring it and so the patients were divided into 4 groups. Lately, as there have been disagreements about how to treat score 2 patients, chromogenic in situ hybridization (CISH) and florescence in situ hybridization (FISH) are introduced. Since CISH method is more convenient than FISH for gene amplification study, FISH has been substituted by CISH.

AIM: The current study is conducted in order to investigate whether using CISH is a better method comparison to IHC method for determines HER2 expression in patients with breast cancer in.

METHODS: In this cross-sectional descriptive analytical study, information of 44 female patients with invasive ductal breast cancer were gathered from Imam Reza and Omid Hospital in Mashhad. IHC staining was done for all patients in order to determine the level of HER2 expression, and after scoring them into 4 groups of 0, +1, +2 and +3, CISH staining was carried out for all 4 groups. At the end, results from both methods were statistically evaluated using SPSS software V.22.0.

RESULTS: The average age of patients was 50.2 with the standard deviation of 10.96. Using IHC method was observed that 2.6% (1 patient), 26.3% (10 patients), 65.8% (25 patients) and 5.3% (2 patients) percentage of patients had scores of 0, +1, +2 and +3. On the other hand, CISH method showed 36 patients (90%) with no amplifications and 4 (10%) with sever amplifications. In a comparative study using Fisher's exact test (p = 0.000), we found a significant relation between IHC method and CISH method indicating that all patients showing severe amplifications in CISH method, owned scores of +2 and +3 in IHC method.

CONCLUSION: According to the present study and comparing the results with similar previous studies, it can be concluded that CISH method works highly effective in determining HER2 expression level in patients with breast cancer. This method is also able to determine the status of patients with score +2 in IHC for their treatment with herceptin


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Darvishi M, Vasei N. Herpes zoster in breast cancer: a case report. J Biomed Res. 2017; 31(4): 370–372. PMid:28808209 PMCid:PMC5548998

Sadjadi A, Nouraie M, Ghorbani A, Alimohammadian M, Malekzadeh R. Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry, 2009.

Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, Ebrahimi M. Breast cancer in Iran: an epidemiological review. The breast journal. 2007; 13(4):383-91. https://doi.org/10.1111/j.1524-4741.2007.00446.x PMid:17593043

King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985; 229(4717):974-6. https://doi.org/10.1126/science.2992089 PMid:2992089

Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clinical breast cancer. 2004; 5(1):63-9. https://doi.org/10.3816/CBC.2004.n.011 PMid:15140287

Mrozkowiak, A., et al., HER2 status in breast cancer determined by IHC and FISH: comparison of the results. Pol J Pathol, 2004. 55(4): 165-71. PMid:15757204

Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM. HER-2 testing in breast cancer using parallel tissue-based methods. Jama. 2004; 291(16):1972-7. https://doi.org/10.1001/jama.291.16.1972 PMid:15113815

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. https://doi.org/10.1126/science.3798106 PMid:3798106

Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer research. 1991; 51(17):4575-80. PMid:1678683

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast Jr RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of clinical oncology. 2007; 25(33):5287-312. https://doi.org/10.1200/JCO.2007.14.2364 PMid:17954709

Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, van de Vijver M. Emerging technologies for assessing HER2 amplification. American journal of clinical pathology. 2009; 132(4):539-48. https://doi.org/10.1309/AJCPV2I0HGPMGBSQ PMid:19762531

Dalvandi M, Nazemi Rafie A, Kamali A, Jamshidifard A. Evaluation of the prognostic value of multimodal intraoperative monitoring in posterior fossa surgery patients with cerebellopontine angle tumors. Eur J Transl Myol. 2018; 28(1): 7260. https://doi.org/10.4081/ejtm.2018.7260 PMid:29686816 PMCid:PMC5895985

Powell WC, Roche PC, Tubbs RR. A new rabbit monoclonal antibody (4B5) for the immuno-histochemical (IHC) determination of the HER2 status in breast cancer: Comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Applied Immunohistochemistry & Molecular Morphology. 2008; 16(6):569. https://doi.org/10.1097/PAI.0b013e3181895d6c PMid:18931613

Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, Christopher CT. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Modern Pathology. 2008; 21(10):1271. https://doi.org/10.1038/modpathol.2008.83 PMid:18487992

Li-Ning-T E, Ronchetti R, Torres-Cabala C, Merino MJ. Role of Chromogenic in Situ Hybridization (CISHâ„¢) in the Evaluation of HER2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish. International journal of surgical pathology. 2005; 13(4):343-51. https://doi.org/10.1177/106689690501300406 PMid:16273190

Wolff AC, HM, et al. ASCO–CAP HER2 Test Guideline Recommendations, 2013.

Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO, Couturier J. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. British journal of cancer. 2003; 88(10):1587. https://doi.org/10.1038/sj.bjc.6600943 PMid:12771927 PMCid:PMC2377115

Viale G, Slaets L, Bogaerts J, Rutgers E, Van't Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell'Orto P, Van Den Akker J. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Annals of oncology. 2014; 25(4):816-23. https://doi.org/10.1093/annonc/mdu026 PMid:24667714 PMCid:PMC3969556

Naseh G, Mohammadifard M, Mohammadifard M. Upregulation of cyclin-dependent kinase 7 and matrix metalloproteinase-14 expression contribute to metastatic properties of gastric cancer. IUBMB Life. 2016; 68(10):799-805. https://doi.org/10.1002/iub.1543 PMid:27562173

Ghaffari SR, Sabokbar T, Dastan J, Rafati M, Moossavi S. Her2 amplification status in Iranian breast cancer patients: comparison of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH). Asian Pac J Cancer Prev. 2011; 12(4):1031-4. PMid:21790246

Takahashi M, Inoue KI, Goto R, Tamura M, Taguchi K, Takahashi H, Suzuki H, Yamashiro K, Ogita M. Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report. Breast Cancer. 2003; 10(2):170. https://doi.org/10.1007/BF02967645 PMid:12736573

Di Palma S, Collins N, Faulkes C, Ping B, Ferns G, Haagsma B, Kissin M, Layer G, Cook M. Chromogenic in-situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. Journal of clinical pathology. 2007. PMCid:PMC1972421

Madrid MA, Lo RW. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Research. 2004; 6(5):R593. https://doi.org/10.1186/bcr915 PMid:15318940 PMCid:PMC549176



How to Cite

Atabati H, Raoofi A, Amini A, Farahani RM. Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma. Open Access Maced J Med Sci [Internet]. 2018 Nov. 19 [cited 2022 Aug. 14];6(11):1977-81. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2018.455



A - Basic Science